The Disease Forecasting Company.
Airfinity analysis on data from the Wegovy trial on cardiovascular outcomes reveals that even after a 65% rebate on the list price, it will cost $1.1m to prevent one heart attack, stroke or cardiovascular death.
What's happening in a given disease area?
Airfinity is the most comprehensive, single source of intelligence for new developments in your chosen area.
Identify the true need for a vaccine or a treatment.
Our suite of dynamic predictive indicators help you navigate highly dynamic and uncertain market developments and see the real opportunities.
Maximise impact to save lives
Our analytics and probabilistic tools inform key decisions on resource allocation, investment and procurement decisions to maximise impact of a given drug or vaccine and ultimately improve as many lives as possible.
Airfinity combines proprietary surveillance tools and forecast models with expert analysis for dozens of infectious diseases, including COVID-19, Monkeypox, Influenza and RSV.
Market & Production
Disease & Prevalence
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
“Vaccine production data from Airfinity has been spot on. In a fast moving pandemic, these forecasts are really important for evidence-based policy making.”
“Airfinity has been critical in furnishing us and the rest of the world with COVID-19 numbers.”
James Fransham, Data Journalist,